The Effects of 5‐Aminosalicylic Acid on Janus Kinase Inhibitor Treatment in Ulcerative Colitis
Bibliographic record
Abstract
To the Editors, we read with interest the article by Nishida et al. [1] investigating the effects of aminosalicylic acid (5-ASA) combined with tofacitinib in ulcerative colitis (UC) patients. They found that concomitant 5-ASA use reduced the risk of relapse in patients on 5 mg tofacitinib BID, suggesting benefits at lower doses. Their findings are important to current clinical practice and future research; we have also performed a retrospective cohort study to evaluate the effects of 5-ASA combined with Janus kinase (JAK) inhibitors including tofacitinib and upadacitinib in UC patients. A total of 156 UC patients participated in this study between January 2020 and October 2024, including 66 (42.3%) women and 90 (57.7%) men. Among these patients, 42 were in tofacitinib 5 mg group, 42 were in tofacitinib 10 mg group, 42 were in upadacitinib 45 mg/30 mg group, and 42 were in upadacitinib 45 mg/15 mg group. Within our cohort, 64.9% of the patients in the tofacitinib 5 mg group and 76.2% of the patients in the tofacitinib 10 mg group received concomitant 5-ASA, 74.4% of the patients in the upadacitinib 45 mg/30 mg group, and 70.6% of the patients in the upadacitinib 45 mg/15 mg group received concomitant 5-ASA. The median disease duration was 1.2, 1.4, 1.2, and 1.5 years in the tofacitinib 5 mg with 5-ASA group, tofacitinib 10 mg with 5-ASA group, tofacitinib 5 mg, and tofacitinib 10 mg, respectively. The median disease duration was 1.3, 1.4, 1.2, and 1.1 years in the upadacitinib 45 mg/30 mg with 5-ASA group, upadacitinib 45 mg/15 mg with 5-ASA group, upadacitinib 45 mg/30 mg, and upadacitinib 45 mg/15 mg, respectively. According to the Montreal classification, the number of patients with E1, E2, and E3 was 36, 87, and 33. Table 1 presents the overall demographic characteristics and provides a detailed comparison between the groups using and not using 5-ASA in the JAK inhibitor group. There were no significant differences about C-reactive protein, fecal calprotectin, hemoglobin, and albumin among these groups. Of the 156 patients, 20 (12.8%) experienced clinical relapse, and 38 (19.2%) experienced endoscopic relapse at the follow-up of 6 months. Of these, 13.6% (6 of 44) of patients not using concomitant 5-ASA clinical relapsed, compared to 12.5% (14 of 112) of those using concomitant 5-ASA. A total of 25% (11 of 44) of patients not using concomitant 5-ASA endoscopic relapsed, compared to 24.1% (27 of 112) of those using concomitant 5-ASA. No significant differences were noted in the clinical and endoscopic relapse rates between patients using only JAK inhibitors and using JAK inhibitors with 5-ASA. At the same time, there were no significant differences about the clinical and endoscopic relapse rates between patients with tofacitinib and upadacitinib. In conclusion, our retrospective cohort study indicated that the concomitant use of 5-ASA cannot offers protective benefits when using JAK inhibitors to treat UC. However, further research is needed to confirm our findings and understand the mechanisms involved. The authors declare no conflicts of interest.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.021 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.003 | 0.001 |
| Research integrity | 0.006 | 0.012 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".